2-(4-aminophenylthio)-quinoline | 190331-31-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-(4-aminophenylthio)-quinoline
• 英文别名: 2-(4-aminophenylthio) quinoline；2-(4-aminophenylthio)quinoline；4-quinolin-2-ylsulfanylaniline
• CAS: 190331-31-8
• 化学式: C₁₅H₁₂N₂S
• mdl: MFCD00092990
• 分子量: 252.34
• InChiKey: GXOORYGDSLJFJZ-UHFFFAOYSA-N

物化性质

• 沸点：
  486.7±25.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,5-二氯-2-羟基苯甲酰氯 、 2-(4-aminophenylthio)-quinoline 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 144.0h， 生成 3,5-Dichloro-2-hydroxy-N-[4-(quinolin-2-ylsulfanyl)-phenyl]-benzamide
  参考文献：
  名称：

  Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors

  摘要：

  Cathepsin D, a lysosomal aspartyl protease, has been implicated in the pathology of Alzheimer's disease as well as breast and ovarian cancer. A weakly active cathepsin D inhibitor was identified by high throughput screening. Subsequent optimization led to the discovery of a new class of small molecule inhibitors of this enzyme, culminating with the sulfonamide 13 (IC50 = 250 nM), (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00433-3
• 作为产物：
  描述：

  2-(p-nitrophenylthio)quinoline 在 钯 乙醚 、 正己烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以to yield 2-(4-aminophenylthio)quinoline 10.0 g, 93%的产率得到2-(4-aminophenylthio)-quinoline
  参考文献：
  名称：

  Chemical compounds as inhibitors of amyloid beta protein production

  摘要：

  公式I的化合物，其中##STR1##Z是O或S; R.sup.11是卤素原子; R.sup.12是卤素原子或三氟甲基基团; X是S，SO，SO.sub.2，O或NH; R.sup.4是萘基，喹啉基，苯并咪唑基，吡啶基，吡嗪基，苯并噁唑基或苯并噻唑基，未取代或取代一个或两个取代基，所述取代基选自卤素原子，(1-4C)烷基，(1-4C)烷氧基，硝基，(1-4C)烷氧羰基，卤代(1-4C)烷基和苯基; 或其药学上可接受的盐。这些化合物可用作淀粉样β-蛋白产生的抑制剂。

  公开号：

  US05624937A1

文献信息

• Chemical compounds as inhibitors of amyloid beta protein production
  申请人：Eli Lilly and Company

  公开号：US05624937A1

  公开（公告）日：1997-04-29

  A compound of the formula I in which ##STR1## Z is O or S; R.sup.11 is a halogen atom; R.sup.12 is a halogen atom or a trifluoromethyl group; and X is S, SO, SO.sub.2, O or NH; R.sup.4 is naphthyl, quinolinyl, benzimidazolyl, pyridyl, pyradazinyl, benzoxazolyl or benzothiazolyl, unsubstituted or substituted by one or two substituents selected from a halogen atom, (1-4C)alkyl, (1-4C)alkoxy, nitro, (1-4C)alkoxycarbonyl, halo(1-4C)alkyl, and phenyl; or a pharmaceutically acceptable salt thereof. The compounds are useful as inhibitors of amyloid beta-protein production.

  一种具有以下式I的化合物：##STR1## 其中Z为O或S；R.sup.11为卤素原子；R.sup.12为卤素原子或三氟甲基基团；X为S、SO、SO.sub.2、O或NH；R.sup.4为萘基、喹啉基、苯并咪唑基、吡啶基、吡啶并咪唑基、苯并噁唑基或苯并噻唑基，未取代或取代为一个或两个取自卤素原子、(1-4C)烷基、(1-4C)烷氧基、硝基、(1-4C)烷氧羰基、卤代(1-4C)烷基和苯基的取代基；或其药学上可接受的盐。这些化合物可用作淀粉样β-蛋白产生的抑制剂。
• Quinoline derivatives and quinazoline derivatives having azolyl group
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：US20030087907A1

  公开（公告）日：2003-05-08

  An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: 1 wherein X and Z represent CH or N; Y represents O or S; R 1 , R 2 , and R 3 represent H, alkoxy or the like; R 4 represents H; R 5 , R 6 , R 7 , and R 8 represent H, halogen, alkoxy or the like; R 9 and R 10 represent H, alkyl or the like; and R 11 represents optionally substituted azolyl.

  本发明的一个目的是提供具有强效抗肿瘤活性的化合物。根据本发明的化合物是由式（I）表示的化合物或其药学上可接受的盐或溶剂：其中X和Z表示CH或N；Y表示O或S；R1、R2和R3表示H、烷氧基或类似物；R4表示H；R5、R6、R7和R8表示H、卤素、烷氧基或类似物；R9和R10表示H、烷基或类似物；R11表示选择性取代的唑基。
• Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
  申请人：Miwa Atsushi

  公开号：US20050049264A1

  公开（公告）日：2005-03-03

  An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously administered, can suppress the growth of cancer cells. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; Q represents NR 10 , CR 11 R 2 , carbonyl, O, S(═O)m, wherein m is 0 to 2, or urea; R 1 to R 3 each independently represent H, OH, halogen, nitro, amino, alkyl, alkoxy or the like in which the alkyl and alkoxy groups are optionally substituted; R 4 represents H; R 5 to R 8 each independently represent H, halogen, alkyl, or alkoxy; and R 9 represents an optionally substituted carbocyclic or heterocyclic group.

  本发明的目标是提供新型化合物，其具有对FGF受体家族自磷酸化的抑制活性，并在口服或静脉注射时能够抑制癌细胞的生长。本发明的化合物由公式（I）或其药学上可接受的盐或溶剂表示：其中X代表CH或N; Z代表O或S; Q代表NR10，CR11R2，羰基，O，S（═O）m，其中m为0到2，或脲基; R1至R3各自独立地表示H、OH、卤素、硝基、氨基、烷基、烷氧基或其类似物，其中烷基和烷氧基基团可选择性地被取代; R4表示H; R5至R8各自独立地表示H、卤素、烷基或烷氧基; R9表示一个可选择性取代的碳环或杂环基团。
• Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
  申请人：Kubo Kazuo

  公开号：US20060235033A1

  公开（公告）日：2006-10-19

  An objective of the present invention is to provide compounds which have inhibitory activity against autophosphorylation of macrophage colony-stimulating factor receptors. The compounds of the present invention are represented by formula (I) and salt and solvate thereof: wherein X represents CH or N; Z represents O or S; R 1 , R 2 , and R 3 represent H, optionally substituted alkoxy or the like; R 4 represents H; R 5 , R 6 , R 7 , and R 8 represent H, halogen, alkyl, alkoxy, trifluoromethyl or the like; R 9 and R 10 represent H, alkyl or the like; and any one of R 11 and R 12 represents H with the other representing alkyl and R 13 represents an optionally substituted carbocyclic or heterocyclic ring or the like, or R 11 represents H and R 12 and R 13 combine together to form a bicyclic carbocyclic ring.

  本发明的目标是提供具有抑制巨噬细胞集落刺激因子受体自磷酸化活性的化合物。本发明的化合物由式（I）及其盐和溶剂化物表示：其中X表示CH或N；Z表示O或S；R1、R2和R3表示H、可选地取代的烷氧基或类似物；R4表示H；R5、R6、R7和R8表示H、卤素、烷基、烷氧基、三氟甲基或类似物；R9和R10表示H、烷基或类似物；R11和R12中的任意一个表示H，另一个表示烷基，R13表示可选地取代的碳环或杂环环或类似物，或R11表示H，R12和R13结合形成双环碳环。
• Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
  申请人：Miwa Atsushi

  公开号：US20080207617A1

  公开（公告）日：2008-08-28

  An objective of the present invention is to provide compounds and pharmaceuticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R 1 , R 2 , and R 3 represent H, OH, or optionally substituted alkoxy; R 4 represents H; R 5 , R 6 , R 7 , and R 8 represent H, Hal, alkyl or the like; and R 9 represents, e.g., alkyl substituted by t-butyl or the like.

  本发明的目标是提供化合物和药物，用于治疗抑制FMS样酪氨酸激酶3（Flt3）自磷酸化在治疗上具有疗效的疾病。本发明涉及一种药物组合物，用于治疗或预防抑制Flt3自磷酸化在治疗或预防上具有疗效的疾病，所述药物组合物包括以下公式（I）所表示的化合物或其药学上可接受的盐或溶剂：其中X代表CH或N；Z代表O或S；R1、R2和R3代表H、OH或可选取代的烷氧基；R4代表H；R5、R6、R7和R8代表H、卤素、烷基或类似物；R9代表例如被t-丁基或类似物取代的烷基。